• Active, not recruiting

NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT

Updated: Oct 4

TOURMALINE-MM3

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

TOURMALINE-MM3

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant


The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response [CR], very good partial response [VGPR], or partial response [PR]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).


Sponsor

Takeda


Multiple locations

International study

 

ClinicalTrials.gov Identifier: NCT02181413

Official Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

First Posted : July 4, 2014


Click here for details on ClinicalTrials.gov


C16019 | Clinical Trial Summary (takeda.com)

 

Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information

 

Drug: Ixazomib Citrate

Drug: Placebo

 

MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials

Blood;2022 Sep 21

Click here for details


Intenational Myeloma Foundation: Measurable Residual Disease Evaluation During Ixazomib Maintenance in NDMM: TOURMALINE-MM3 and -MM4

Jun 16, 2021

Click here for details


Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial

Eur J Haematol; 2020

https://pubmed.ncbi.nlm.nih.gov/31880006/


Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

Ann Hematol;2020

https://pubmed.ncbi.nlm.nih.gov/32613281/


Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Lancet; 2019 Jan

https://pubmed.ncbi.nlm.nih.gov/30545780/

 

Locations

United States, Minnesota

United States, New York

United States, Texas

United States, West Virginia

Mexico

Canada, Ontario

South America

Brazil

Argentina

Colombia

Australia, Queensland

Australia, South Australia

Australia, Victoria

Australia, New South Wales

Europe

United Kingdom

Austria

Belgium

Europe

Czechia

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Norway

Poland

Portugal

Spain

Sweden

Switzerland

Turkey

Ukraine

Asia

Israel

Japan

Korea, Republic of

Singapore

Taiwan

Thailand

South Africa

 

RELATED POSTS

MCT: MYELOMA CLINICAL TRIALS WITH IXAZOMIB


NCT02312258: TOURMALINE-MM4 - Phase 3: A Study of Oral Ixazomib Maintenance Therapy in Participants With NDMM-TIE

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Click here for details


NCT02181413: TOURMALINE-MM3 - Phase 3 - Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

Click here for details


NCT01850524: TOURMALINE-MM2 - Phase 3 - Comparing Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Click here for details


NCT01564537: TOURMALINE-MM1 - Phase 3 - Comparing Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex RRMM

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Click here for details


NCT03941860: EAA171 - OPTIMUM - Phase 3 - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma

Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)

Click here for details


NCT03720041: Myeloma XIV - (FiTNEss) - Phase 3: Frailty-adjusted Therapy in Transplant Non-Elig. NDMM

Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I)

Click here for details


NCT03651128: (KarMMa-3) - Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma RRMM

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Click here for details


NCT03562169: Myeloma XII (ACCoRd) - Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM

A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma

Click here for details


NCT02406144: GEM2014MAIN - Phase 3 - Maintenance Lenalidomide, Dex VS Lenalidomide, Dex. & MLN9708 After ASCT NDMM

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

Click here for details


NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM

Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma

Click here for details


NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib RRMM

Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma

Click here for details







Posts Archive